CRESCENT BIOPHARMA, INC. — Director's Dealing 2021

May 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2021-05-18

Reporting Person: JUNIUS DANIEL M (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-18	Common Stock	A	5250	$0.00	Acquired	43250	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-18	Stock Option (right to buy)	$2.55	A	10500	Acquired	2031-05-17	Common Stock (10500)	Direct

Footnotes

F1: The security represents restricted stock units granted to the reporting person. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F2: The shares underlying these restricted stock units vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date.

F3: The shares underlying this option vest on May 18, 2022, subject to the reporting person's continuous service as of such vesting date.